A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Napabucasin (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
- Indications Cancer
- Focus Adverse reactions
- Sponsors Boston Biomedical
- 11 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 03 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 17 Jul 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017, according to ClinicalTrials.gov record.